Therafusol Injection

Adult dosage

Administer 500 to 1000 mL by drip infusion. The infusion rate should be based on 180 to 300 minutes for 500 mL (approximately 40 to 50 drops per minute). For central venous administration, mix 500 to 1000 mL with dextrose and administer continuously in the central vein for 24 hours.

This medication must be used according to a doctor's instructions. It should not be administered to patients with severe renal dysfunction or high nitrogen levels in the blood. Patients with metabolic disorders affecting amino acid metabolism aside from liver dysfunction should also not use this medication. Administration should be avoided in patients with metabolic disorders that affect nitrogen utilization, severely weakened heart failure patients, and patients with pulmonary edema. Patients with anuria or oliguria, those with excessive acidification (acidosis), and patients with excess hydration should not use this medication. Patients with congestive heart failure or severe heart failure, those with significant sodium retention and edema, and patients with impaired renal function must use this medication cautiously. This medication contains sodium bisulfite, which may cause allergic reactions, especially in asthmatic patients, where there is a higher risk of asthma attacks. Rarely, hypersensitivity reactions such as rash may occur; if such symptoms develop, use should be discontinued immediately. Gastrointestinal symptoms such as nausea or vomiting may occur occasionally. Cardiovascular symptoms such as chest discomfort, palpitations, rapid heartbeat, and elevated blood pressure may also occur. Rapid and high doses of this medication may lead to acidosis due to acidification of the body. Occasional symptoms such as chills, fever, headache, difficulty breathing, respiratory arrest, shock, bronchospasm, and urinary tract spasm may appear. Metabolic acidosis, hypophosphatemia, alkalosis, elevated blood glucose, diabetes, dehydration, liver dysfunction, vitamin deficiencies or excesses, and electrolyte imbalances may occur, so care must be taken. Patients with poor renal function may experience elevated blood urea nitrogen levels. Blood ammonia levels may vary depending on the therapeutic effect, so regular monitoring is necessary. Caution is required regarding electrolyte balance in cases of large doses, as overdose may lead to alkalosis. Patients with a history of kidney disease, lung disease, or heart disease should be monitored carefully to avoid excessive fluid shifts. Diabetic patients should frequently monitor their blood sugar levels while using this medication. This medication may reduce the protein-sparing effect when used with certain antibiotics. Its safety has not been established in pregnant women; it should be administered only if the therapeutic benefit outweighs the risks. In children, hepatic function may be immature, so the concentration should be kept low and blood ammonia levels should be checked frequently. Elderly patients may have reduced body functions, so the infusion rate should be slow, and doses should be reduced as necessary. This medication contains electrolytes; caution should be taken regarding electrolyte balance in cases of large doses, and it should be infused slowly. Rapid infusion may cause chills or vomiting, and excessive amounts of amino acids may be excreted via the kidneys, so caution is necessary. Use at room temperature and thoroughly maintain aseptic conditions during solution preparation. Do not use if the solution is cloudy or discolored, and use quickly after opening, storing in the refrigerator for use within 24 hours. Do not use if packaging or containers are damaged, and ensure measurements are accurate based on container markings. It is safer not to administer to patients with a history of myocardial infarction.

Serious side effects

• Anaphylactic shock
• difficulty in breathing
• respiratory arrest
• shock
• bronchospasm
• chills
• fever.

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• tachycardia
• elevated blood pressure
• metabolic acidosis
• hypophosphatemia
• alkalosis

This medication should be stored in a sealed container to prevent exposure to air and should be kept away from direct sunlight at room temperature. Room temperature generally refers to temperatures between 15 to 25 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent deterioration.

Appearance

A colorless to pale yellow transparent injection solution contained in a colorless transparent glass vial with a rubber stopper suitable for injection.

Package unit

100mL vial, 250mL vial